Atlas FDA

Medtronic Altaviva System

FDA premarket approval P240011/S004 · decided 2025-12-19

Approval details

PMA number
P240011
Supplement
S004
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
Medtronic Altaviva System
Generic name
Stimulator, tibial, electrical, implantable, for urinary incontinence
Applicant
Medtronic Neuromodulation
Date received
2025-11-21
Decision date
2025-12-19
Days to decision
28 days
Decision code
APPR
Product code
QPT
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Minneapolis, MN
Statement
The protocol modifications include the addition of quality-of-life, work productivity, mental health, and sexual health questionnaires. Additional revisions included changing "up to 30 institutions" to "approximately 30 institutions", requirements for appropriate investigator training, education, and experience, and updated language regarding the 6-month washout period for botulinum toxin therapy and sacral neuromodulation.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
SureTune4 Software (DEN210003)Medtronic Neuromodulation2021-08-23